Showing results for 
Search instead for 
Did you mean: 

Highlights from the COSA19 conference

Content Creator
0 0 76

This November, members of PCFA attended COSA19, the annual meeting of the Clinical Oncology Society of Australia. The COSA meeting brings together clinicians, nurses, allied healthcare and scientists to discuss the clinical management and supportive care for cancer. At this year’s meeting urological cancer was a special theme, meaning there were many prostate cancer presentations. Numerous sessions were dedicated to prostate cancer as well as other important aspects of cancer treatment and care. Some of the highlight sessions were digital health, euthanasia issues and end-of-life care, living with the after-effects of prostate cancer and an opening session dedicated to the future of prostate cancer management.

Here we present some of the important prostate cancer presentations at COSA19:3718094303?profile=RESIZE_710x

Latest developments in prostate cancer surgery and active surveillance 

Asst. Prof. Stacey Loeb, New York University, USA

Asst. Prof. Stacey Loeb described the management of localised prostate cancer in the USA and Australia. She described how the use of active surveillance by men with low-risk prostate cancer has reduced the problem of over-treatment. Between 2011 and 2013, 40-49% of men in the USA managed their low-risk prostate cancer by observation rather than immediate treatment. This number in Australia is now close to 75%. Active surveillance means forgoing or delaying treatment until it becomes necessary. It involves regularly monitoring the cancer with PSA tests, biopsies or MRI scans. The reduction of overtreatment in the USA has been an important influence, leading to a change in guidelines towards increasing the use of PSA testing. There are many challenges for active surveillance that need to be improved with research. These include issues with multiple biopsies, determining the best stage at which to commence treatmen and too many men leaving the active surveillance program.

In Australia, the majority of men with intermediate-risk prostate cancer choose surgery. Surgery for high-risk prostate cancer is increasing in popularity too. Medicare data show that over 80% of prostate cancer surgeries in Australian are now robotic-assisted. Asst. Prof Loeb described advances in surgery and the 3718095200?profile=RESIZE_710xlatest new inventions that will likely affect the future of prostate surgery. These are new surgical techniques currently being developed that are not standard care in Australia. They include robotic-assisted surgery that uses a single keyhole incision (see picture), new robotic systems from different companies and Retzius-sparing surgery – a technique with improved urinary continence outcomes. The Menon precision prostatectomy technique aims to leave the prostate capsule (outer layer of the gland) intact. A biopsy is done immediately to detect the extent of the tumour, determining how much of the prostate to remove. This approach aims to help improve erections and sexual function by reducing the damage from the operation, where possible.

Precise and Personalised: Radiation therapy for prostate cancer in 2019

A/Prof Sandra Turner, Crown Princess Mary Cancer Centre, NSW

A/Prof Turner spoke about the current status and future innovations in radiotherapy for prostate cancer in Australia.

Radiotherapy for prostate cancer in Australia is most commonly delivered by external radiation beams. The radiation is carefully focussed at the prostate to damage the cells in the gland, stopping them from dividing and killing them. Cancerous cells are more likely to be affected than normal prostate cells. Alternatively, brachytherapy delivers radiation to the prostate via radioactive seeds that are implanted into the gland. This can be done by high or low dose, and in combination with external beams of radiotherapy. Radiotherapy can be a cure for localised prostate cancer as well as a treatment for pain for men with metastatic prostate cancer.

A/Prof Turner described advances in radiotherapy as aiming to:

-improve targeting of the cancer, leading to higher dose to the tumour and higher cure rates

-reduce of the dose to normal tissues, reducing side effects

-improve quality-of-life and the patient’s experience of the treatment

A recent innovation that aims to reduce side effects is SpaceOAR. SpaceOAR involves extra “filling” inserted between the prostate and the bowels, to push them apart. Using SpaceOAR has the potential to reduce the radiation dose to the bowels, reducing bowel side effects.3718095970?profile=RESIZE_710x

Another important innovation is the use of Stereotactic Body Radiation Therapy (SBRT), also called SABR and ultra-hypofractionation. During this therapy, a higher radiation dose is used over fewer treatment sessions. This is becoming a more common approach for treating localised prostate cancer. SBRT/SABR can also be used by men with oligometastatic prostate cancer – who have a few small tumours that have spread to distant regions. SBRT/SABR is also used to prevent imminent spinal cord compression, a serious compilation caused by tumours growing in the spine.

A/Prof Turner described radiomics, a promising area of research that is being developed for prostate cancer. Radiomics is a process by which a vast amount of information from scans and tests is used to make clinical decisions and predict outcomes. Information from MRI and PSMA-PET scans is used to predict cancer location, cancer cell density, aggressiveness and sensitivity to radiotherapy treatment.

Ten-year quality-of-life outcomes in men with prostate cancer

A/Prof Nick Ralph, Cancer Council Queensland and University of Southern Queensland

A/Prof Nick Ralph spoke about prostate cancer survivorship in Australia. Survival rates from prostate cancer are relatively high in Australia. 90% of men diagnosed with this disease remain alive 10 years by after their diagnosis. There are over 200,000 men living in Australia after a diagnosis with prostate cancer. Around 67,000 of these men live in regional Australia. The purpose of this study was to track the quality-of-life of men with prostate cancer over a period of 10 years.

This Australia-wide study recruited 1,064 men newly-diagnosed with prostate cancer. By 10 years, 598 men remained in the study and completed the surveys. Most of these men (92%) had localised prostate cancer. The surveys collected information about the life satisfaction (as related to their health), their symptoms and issues with side effects of sexual function, urinary and bowel incontinence. The study showed that 35–40% of these men experienced poorer physical and mental quality-of-life and life satisfaction 10 years after their diagnosis and treatment. Symptoms of the disease were a greater problem for men with multiple conditions, those treated with hormone therapy, and those from disadvantaged areas.

Results from this study showed that 8 years after diagnosis, urinary function started to decrease, whereas sexual function increased a little. Unsurprisingly, men who had better sexual, urinary or bowel function reported a better quality-of-life. Interestingly, bowel function had larger effect on quality-of-life than sexual or urinary function. These findings show the importance of these treatment side effects and symptoms for the life satisfaction of these men.3718096623?profile=RESIZE_710x

A/Prof Ralph made some recommendations on the basis of the results of this study. The risk indicators (hormone therapy, multiple conditions and disadvantaged background) should be incorporated into survivorship care plans to help bring appropriate care to men at highest risk of poor physical and mental health. Men with prostate cancer should be assessed for these factors and provided with life-long prostate cancer survivorship care.

Prostate cancer risk factors in the NSW 45 and up study

Dr Visalini Nair-Shalliker, Cancer Council NSW

Dr Nair-Shalliker has completed a study using data from a huge study of NSW people. The 45 and Up study is the largest ongoing study of healthy ageing in the Southern Hemisphere. Over 250,000 people from NSW have joined the 45 and Up study. They were enrolled between 2006 and 2009. People were interviewed at the start of the study and at regular intervals since. The interviews asked about medical history, social and education factors and health behaviours such as diet and smoking. Volunteers gave permission for data linking so claims through Medicare and prescription records could be accessed.

The ultimate aim of the 45 and Up study is to link risk factors with disease outcomes. This is called a cohort study. Results from cohort studies can link many different diseases to many different risk factors, rather than focusing on one disease. Numerous researchers are using the 45 and Up study to find out more about the risk factors for prostate cancer.

Dr Nair-Shalliker used data from the 45 and up study to identify risk factors for prostate cancer in the NSW population. In total, there were over 91,000 male participants in the study who had provided enough information to be include in the prostate cancer subset. 3,701 of these men were diagnosed with prostate cancer since the start of the study. The analysis took into account differences in characteristics such as age, place of residence, income and others. Results showed that a family history of prostate cancer was a risk factor for diagnosis – consistent with results from many other studies. This was particularly so for men with a first degree relative with prostate cancer, such as a father or brother. Height, weight, smoking and alcohol consumption were not risk factors for these men. As expected, lower urinary tract symptoms were also associated with prostate cancer diagnosis.

The most interesting finding from this study was that men with diabetes that is treated (e.g. with metformin) had a lower risk of prostate cancer diagnosis. This was true of all stages of prostate cancer. This study adds to an increasing amount of evidence pointing to metformin’s positive effects for men with prostate cancer.

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.